New conformationally restricted analog of the immunosuppressory mini-domain of HLA-DQ and its biological properties

Peptides

Volumn 21, Issue 12, 2000, Pages 1849-1858

  Szewczuk, Zbigniew ^a   Wilczyński, Andrzej ^a   Dyba, Marcin ^a   Petry, Inga ^a   Siemion, Ignacy Z ^a   Wieczorek, Zbigniew ^b  

^a UNIVERSITY OF WROC AW   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Cyclic peptide analog; Histocompatibility antigen; Immunosuppressors; Proteolytic stability; RGD sequence; Thymopentin analogs

Indexed keywords

CYCLOPEPTIDE; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; THYMOPENTIN DERIVATIVE; TRYPSIN; ACETYLTHREONYLPROLYLGLUTAMINYLARGINYLGLYCYLASPARTYLVALYLLYSYL (EPSILON ACETYL)THREONINE; CYCLO(SUCCINYLTHREONYLPROLYLGLUTAMINYLARGINYLGLYCYLASPARTYLVALYLLYSYL)THREO NINE; EPITOPE; NONAPEPTIDE; THREONYLPROLYLGLUTAMYLARGINYLGLYCYLASPARTYLVALYLTYROSYLTHREONINE; THYMOPENTIN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELLULAR IMMUNITY; CHEMICAL STRUCTURE; CIRCULAR DICHROISM; CONTROLLED STUDY; CYCLIZATION; HISTOCOMPATIBILITY COMPLEX; HUMORAL IMMUNITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; AMINO TERMINAL SEQUENCE; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG DEGRADATION; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; IMMUNOSUPPRESSIVE TREATMENT; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; STRUCTURE ANALYSIS;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CIRCULAR DICHROISM; CRYSTALLOGRAPHY, X-RAY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPES; HLA-DQ ANTIGENS; HYPERSENSITIVITY; MICE; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA; PEPTIDE BIOSYNTHESIS; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; SPLEEN; THYMOPENTIN; TIME FACTORS;

EID: 0034528243     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(00)00333-8     Document Type: Article

References (37)

1. The refined 2.0 A X-ray crystal structure of the complex formed between bovine β-trypsin and CMTI-I, a trypsin inhibitor from squash seeds (Cucurbita maxima). Topological similarity of the squash seed inhibitors with the carboxypeptidase A inhibitor from potatoes
2. Inhibition of cell cycle progression by a synthetic peptide corresponding to residues 65-79 of an HLA class II sequence: Functional similarities but mechanistic differences with the immunosuppressive drug rapamycin
3. A site for CD4 binding in the b1 domain of the MHC class II protein HLA-DR1
4. 3-Dimensional structure of the human class-II histocompatibility antigen HLA-DR1
5. Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules
6. Immunosuppressive activity of hymenistatin I
7. Definition of the alpha 2 region of HLA-DR molecules involved in CD4 binding
8. The preparation of Merrifield-resin through estrification with cesium salts
9. Structural analysis of class II major histocompatibility complex proteins
10. IUPAC-IUB ICBN Nomenclature and symbolism for amino acids and peptides
11. Influence of dose and route of antigen injection on the immunological induction of T cells
12. Immunization of dissociated spleen cell cultures from normal mice
13. HLA-derived peptides as novel immunomodulatory therapeutics
14. A nomenclature system for labeling cyclic peptide fragments
15. Novel structural features of the human histocompatibility molecules HLA-DQ as revealed by modeling based on the published structure of the related molecule HLA-DR
16. The evaluation of type I and type II β-turn mixtures. Circular dichroism, NMR and molecular dynamics studies
17. Quantitative analysis of cyclic β-turn models
18. Constrained peptides: Models of bioactive peptides and protein substructures
19. Proposal for a common nomenclature for sequence ions in mass spectra of peptides
20. Bioactive peptide design based on protein surface epitopes. A cyclic heptapeptide mimics CD4 domain 1 CC′ loop and inhibits CD4 biological function
21. Synthetic peptides derived from the fourth domain of CD4 antagonize off function and inhibit T cell activation
22. On the size of the active site in proteases
23. Synthesis and activity profiles of novel cyclic opioid peptide monomers and dimers
24. To the problem of biologically active conformation of enkephalin
25. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide
26. Leukocyte integrins
27. Conformationally restricted thrombin inhibitors resistant to proteolytic digestion
28. Conformational modification of PRP-hexapeptide by direct covalent attachment of aromatic side chain groups
29. Synthesis and biological activity of new conformationally restricted analogues of pepstatin
30. Immunological properties of the thymopentin-like fragments of HLA-DQ
31. The immunosuppressory and adhesive mini-region of the human major histocompatibility protein, HLA-DQ
32. Further investigations on thymopentin-like fragments of HLA-DQ and their analogues
33. Immunosuppressory mini-regions of HLA-DP and HLA-DR
34. The unusually high immunomodulatory activity of thymopentin analogue Pro5-TP-5
35. Circular dichroism in peptides
36. Secondary and conformational specificities of trypsin and chymotrypsin
37. Identification of CD4 and major histocompatibility complex functional peptide sites and their homology with oligopeptides from human immunodeficiency virus type 1 glycoprotein gp120: Role in AIDS pathogenesis